HLX-18

N/A

Report date: 2026/04/09 20:00:21

Base Information

Drug NameHLX-18
Drug Alias NameHLX18HLX-18
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionAnti-PD-1
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsCardia CancerSolid tumoursEsophageal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesShanghai Henlius Biologics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Henlius Biologics Co LtdShanghai Henlius Biotech Inc
Inactive CompaniesN/A
Active IndicationsCardia CancerSolid tumoursEsophageal Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A